Pantoprazole + DomperidoneThird Party Manufacturing in India

Pantoprazole + Domperidone works through a dual mechanism that targets both acid secretion and gastric motility. Pantoprazole, a proton pump inhibitor, selectively binds to the H⁺/K⁺-ATPase enzyme system on the secretory surface of gastric parietal cells. This binding irreversibly inhibits the proton pump, blocking the final step of gastric acid production and suppressing both basal and stimulated gastric acid secretion. Domperidone, a dopamine D₂ receptor antagonist, works peripherally on the gastrointestinal tract by blocking dopamine receptors in the gastric wall. This action enhances gastric motility, accelerates gastric emptying, and improves gastro-duodenal coordination. It also exerts antiemetic effects by acting on the chemoreceptor trigger zone located outside the blood-brain barrier. Together, pantoprazole reduces gastric acid production while domperidone prevents acid reflux by promoting forward movement of gastric contents. This complementary action makes the combination particularly effective for gastroesophageal reflux disease that does not respond to pantoprazole alone, as it addresses both the chemical irritant and the mechanical dysfunction underlying the condition.

Therapeutic Uses

Pantoprazole + Domperidone is prescribed for the treatment of:

• Gastroesophageal Reflux Disease (GERD): Particularly effective in cases where pantoprazole alone does not provide adequate symptom relief. The combination addresses both acid hypersecretion and delayed gastric emptying.
• Heartburn and Acid Regurgitation: Provides rapid relief from the burning sensation caused by stomach acid flowing back into the esophagus.
• Dyspepsia: Manages functional dyspepsia symptoms including epigastric pain, bloating, and early satiety associated with gastric motility disorders.
• Nausea and Vomiting: Domperidone's antiemetic action helps control nausea associated with reflux disease and other gastrointestinal conditions.
• Gastroparesis: Improves gastric emptying in patients with delayed gastric emptying, including diabetic gastroparesis.

Why Manufacturers Choose Pantoprazole + Domperidone

This fixed-dose combination is one of the most widely prescribed gastrointestinal therapies in the Indian pharmaceutical market. The combination offers a large volume opportunity for third party manufacturers, with consistent demand from both the domestic PCD franchise network and export markets across Africa, Southeast Asia, and the Middle East. Pantoprazole + Domperidone tablets are manufactured under WHO-GMP certified facilities using high-quality APIs sourced from approved suppliers, ensuring batch consistency and regulatory compliance for global distribution.

This makes Pantoprazole + Domperidone one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.